Hepatic abscess secondary to a duodenal- jejunal bypass liner successfully treated with antibiotics without removal of the device

Bob Ryder; Russell Drummond; Piya Sen Gupta

doi:10.15277/bjd.2024.445

Authors

Dr Robert E J Ryder City Hospital, Birmingham
Professor Russell Drummond North Glasgow Diabetes, Endocrinology & Clinical Pharmacology, Glasgow, UK.
Dr Piya Sen Gupta Department of Diabetes, Guy’s and St Thomas’ Hospital London, UK.

DOI:

https://doi.org/10.15277/bjd.2024.445

Keywords:

hepatic abscess, liver abscess, antibiotics, case report, duodenal-jejunal bypass liner, DJBL, EndoBarrier, RESET, diabetes, obesity, weight loss

References

International Diabetes Federation. IDF diabetes atlas, 10th ed. 2021. https://www.diabetesatlas.org/ (accessed 09 January 2024).

Nice.org.uk. 2023. 1 Recommendations | Obesity: identification, assessment and management | Guidance | NICE. [online] Available at: https://www.nice.org.uk/guidance/cg189/chapter/1-Recommendations#bariatric-surgery-for-people-with-recent-onset-type-2-diabetes (accessed 09 January 2024).

Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2021;397(10271):293-304. https://doi.org/10.1016/S0140-6736(20)32649-0

Dixon JB. Regional differences in the coverage and uptake of bariatric-metabolic surgery: a focus on type 2 diabetes. Surg Obes Relat Dis 2016;12:1171–7. https://doi.org/10.1016/j.soard.2015.11.027

Fung M, Wharton S, Macpherson A, Kuk JL. Receptivity to bariatric surgery in qualified patients. J Obes 2016;2016:5372190. Epub 2016 Jul 19. https://doi.org/10.1155/2016/5372190

Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care 2018;41(5):1106–15. https://doi.org/10.2337/dc17-1985

Ryder REJ, Yadagiri M, Burbridge W, et al. Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the first National Health Service (NHS) EndoBarrier service. Br J Diabetes 2022;22:82-6. https://doi.org/10.15277/bjd.2022.351

Thompson CC, Jirapinyo P, Brethauer S, et al. A multicenter randomized sham-controlled trial of a duodenal jejunal bypass liner for the treatment of type 2 diabetes mellitus. Gastrointestinal Endoscopy 2022;95(Suppl):AB10-AB11. https://doi.org/10.1016/j.gie.2022.04.076

Ryder REJ, Laubner K, Benes M, et al. Endoscopic duodenal-jejunal bypass liner treatment for type 2 diabetes and obesity: glycemic and cardiovascular disease risk factor improvements in 1,022 patients treated worldwide. Diabetes Care 2023;46:e89–e91. https://doi.org/10.2337/dc22-1952

Ruban A, Ashrafian H, Teare JP. The EndoBarrier: duodenal-jejunal bypass liner for diabetes and weight loss. Gastroenterology Research Practice 2018; 2018: Article ID 7823182. https://doi.org/10.1155/2018/7823182

Randomisation to Endobarrier alone Versus with Incretin analogue in SustainEd Diabesity (REVISE-Diabesity). https://classic.clinicaltrials.gov/ct2/show/NCT02055014 (accessed 20 Feb 2024)

Ryder REJ, Yadagiri M, Burbridge W, et al. The United Kingdom’s first NHS EndoBarrier service for long-standing poorly controlled type 2 diabetes and obesity: outcomes one year after EndoBarrier removal. Br J Diabetes 2021;21:76-83.

Ryder REJ, Yadagiri M, Burbridge W, et al. EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients. Practical Diabetes 2022;39(3):13-16a. https://doi.org/10.1002/pdi.2393

Caiazzo R, Branche J, Raverdy V, et al. Efficacy and safety of the duodeno-jejunal bypass liner in patients with metabolic syndrome. Annals Surgery 2020;272(5):696-702. https://doi.org/10.1097/SLA.0000000000004339

https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103235 (accessed 16 Jan 2024)